Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services
  • HHS Invests in Modernizing U.S. Manufacturing Capacity for Pandemic Influenza Vaccine

    To prepare for the next influenza pandemic, BARDA is investing $226 million to increase U.S. manufacturing capacity of Sanofi Pasteur’s recombinant influenza vaccine, which is faster and more flexible than traditional egg-based technology.


    Image of the flu viron  


PHE Newsroom

Submit an Inquiry


Watch, Listen, Subscribe

Facebook Twitter YouTube Email via GovDelivery LinkedIn ​​​
​​ ​​ ​​
  • This page last reviewed: December 12, 2019